



## **ERA-NET NEURON**

**Call for Proposals for Multinational and Translational  
Research Projects on**

# **“INTERDISCIPLINARY APPROACHES TO THE NEUROSCIENCE OF PAIN”**

**Submission deadline for pre-proposals: 6<sup>th</sup> March 2025, 14:00 CET**

### **Electronic proposal submission**

For further information, visit our website:

<http://www.neuron-eranet.eu>

or contact the

#### **NEURON Joint Call Secretariat:**

Dr. Sophia Schach & Dr. Vera Mönter-Telgen

German Aerospace Centre Project Management Agency, DLR-PT

Phone: +49 228 3821 2184

E-Mail: [neuron-eranet@dlr.de](mailto:neuron-eranet@dlr.de)

## 1. Purpose

Maintenance, improvement, and restoration of human health are of fundamental importance and a worldwide priority. Pain poses a significant global health challenge. At present, an estimated 20 per cent of the population suffers from chronic pain worldwide. Chronic pain describes persistent or recurrent pain that lasts longer than three months, irrespective of its cause. It has a devastating impact on those affected, their families, and society, as it contributes to a decreased quality of life, reduced ability to perform activities of daily living and work-related tasks, and significant healthcare costs.

Acute pain is an important warning signal of a threat to the body, such as an injury or a disease. Under certain circumstances, pain can persist despite successful treatment of the underlying condition, or because an underlying condition cannot be identified or treated successfully and becomes chronic. Despite its high prevalence, the mechanisms that cause and maintain chronic pain are still poorly understood. Chronic pain remains underdiagnosed and undertreated. It is a highly complex and subjective experience that can only be understood when considering the dynamic interplay of biological, psychological and social factors.

Due to the psychosocial factors of pain as well as the variety of mechanisms involved in the development of chronic pain, including peripheral and central nervous system mechanisms, interdisciplinary research approaches are needed to develop a better understanding of chronic pain, to improve its management, and ultimately to alleviate pain for the people affected. Research into the neuroscience of pain has the potential to enable earlier and more accurate diagnoses and facilitate the development of innovative, safe, effective, and accessible treatment strategies that recognise individual differences, paving the way for personalised pain management.

The 'Network of European Funding for Neuroscience Research' (NEURON) has been established under the ERA-NET scheme of the European Commission ([www.neuron-eranet.eu](http://www.neuron-eranet.eu)). The ERA-NET NEURON aims to coordinate and optimise research efforts and funding programmes of its partner countries/regions in the field of mental, neurological, and sensory disorders. Under the umbrella of NEURON, a joint transnational call (**JTC 2025**) in the field of **neuroscience of pain** is now launched. The following funding organisations have agreed to fund the joint call for multinational research projects in this scientific area. The call will be conducted simultaneously by the respective national and regional funding organisations and coordinated centrally by the Joint Call Secretariat.

National Health and Medical Research Council (NHMRC)	Australia*
Fonds de la Recherche Scientifique-FNRS (F.R.S.-FNRS)	Belgium*
Ministry of Science, Education and Youth (MSEY)	Croatia
French National Research Agency (ANR)	France*
Federal Ministry of Education and Research (BMBF)	Germany
German Research Foundation (DFG)	Germany
National Research, Development, and Innovation Office (NKFIH)	Hungary
Health Research Board (HRB)	Ireland
Chief Scientist Office, Ministry of Health (CSO-MOH)	Israel*
Italian Ministry of Health (IT-MoH)	Italy
Latvian Council of Science (LZP)	Latvia
Research Council of Lithuania (LMT)	Lithuania
The Research Council of Norway (RCN)	Norway
National Centre for Research and Development (NCBR)	Poland
Executive Agency for Higher Education, Research, Development & Innovation Funding (UEFISCDI)	Romania
Slovak Academy of Sciences (SAS)	Slovakia
Swiss National Science Foundation (SNSF)	Switzerland*
National Science and Technology Council (NSTC)	Taiwan
The Scientific and Technological Research Council of Türkiye (TUBITAK)	Türkiye*
Medical Research Council (MRC)	UK

\*Funding organisations with parallel national application procedures or extra requirements for submission. We strongly recommend contacting the respective funding organisation for further information (contacts, see Annex I).

## 2. Aim and scope of the call

The aim of the call is to facilitate multinational, collaborative research projects that will address critical translational and clinical questions using interdisciplinary approaches to improve the knowledge about the **neuroscience of pain**, bearing the potential to improve the lives of the people affected.

Chronic pain is associated with structural and functional changes in different brain regions and is linked to altered neurotransmitter levels. Such changes can also be accompanied by emotional, cognitive and behavioural impairment. People affected by chronic pain have an increased risk of mental disorders such as depression and anxiety and vice versa. The occurrence of those comorbidities hinders effective pain management and therapy. Thus, significant progress in the field of pain research can only be achieved through coordinated collaboration between different disciplines, including e.g. clinical neurology and psychiatry, psychology, cognitive neuroscience, neurobiology, physiology, genetics, or pharmacology, among others.

The present call aims to fund preclinical and clinical research up to proof-of-concept clinical studies<sup>1</sup> addressing the neuroscience of pain. Research areas may cover a broad range of aspects such as biomarkers, clinical phenotyping, intra- and inter-individual differences, the role of neuroplasticity and

<sup>1</sup> Eligibility and funding requirements for clinical trials vary between the partner countries. Clarification may be obtained from the individual funding organisations

plasticity in the nociceptive system, neuroinflammation, sensitisation and persistence, genetic, epigenetic and molecular mechanisms (neuronal and non-neuronal) as well as the psychological impact of chronic pain and its management. The development of (multimodal) preventive, diagnostic and/or therapeutic approaches based on pathophysiological mechanisms are within the scope of the call. Pharmacological studies and technological developments, including the integration of artificial intelligence, are also included. If clinical diagnoses are relevant to the project, the applicants should aim to use the chronic pain classification of the International Classification of Diseases 11<sup>th</sup> Revision (ICD-11) including, among others, chronic primary pain, chronic post-surgical or post-traumatic pain, chronic secondary musculoskeletal pain, and chronic neuropathic pain. Research on headache, including e.g. migraine or cluster headache, is within the scope of the call if the research proposal clearly considers cross-cutting, transdisciplinary and transdiagnostic aspects applicable to other chronic pain syndromes. Research proposals that focus solely on acute pain, without establishing a connection to chronic pain, are outside the scope of this call. It should be made clear by applicants how their projects will contribute to alleviating chronic pain for patients in clinical practice.

The ERA-NET NEURON funding organisations particularly wish to promote multi-disciplinary work and translational research proposals that combine basic and clinical approaches. The involvement of clinical research groups is strongly encouraged. The consortia should submit novel, ambitious ideas that can only be achieved by the complementary collaboration between partners.

Research proposals should cover at least one of the following areas:

- a) Fundamental research on neuroscientific aspects of the pathogenesis, aetiology, prevention, progression, and treatment of chronic pain. This may include the development of innovative or shared resources and technologies considered of relevance in the context of this call.
- b) Clinical research to develop new strategies for prevention, diagnosis, patient stratification, therapy, and rehabilitation procedures for chronic pain syndromes.

Research on pain-related aspects of neurodegenerative disorders that are addressed by the EU Joint Programme – Neurodegenerative Disease Research (JPND)<sup>2</sup> **is excluded from this call.**

Applicants should demonstrate that they have the expertise and skills required to conduct the study, including already established external collaborations.

The translational value for human disease must be addressed explicitly in the proposals. If used, the choice of the animal model must be justified in the context of human pathology. The use of existing animal models and the usage of infrastructures offering access to existing models is encouraged. The development of new animal or cell models is allowed if clearly justified and only if appropriate models are not available.

Understanding sex and gender differences in the pathogenesis and management of pain is essential for

---

<sup>2</sup> Alzheimer's disease and other neurodegenerative dementias, Parkinson's disease (PD) and PD-related disorders, Prion disease, Motor neuron diseases, Huntington's disease, Spinocerebellar ataxia, Spinal muscular atrophy

the development of targeted and personalized treatment strategies. Therefore, the consideration of sex differences in the studies is mandatory. An explicit justification is required if only one sex is considered. In the case of human studies, gender effects must be considered where appropriate<sup>3</sup>.

To promote equality, diversity and inclusion in the proposals submitted to this call, applicants are strongly encouraged to consider further diversity characteristics of the target groups (e.g. age, ethnicity, cultural, geographic area, economic and educational background). It should be explained how this is appropriately addressed in the projects.

Clinical studies are eligible up to the point of proof of concept<sup>4</sup>. Multimodal and multicentre clinical studies are highly encouraged. ERA-NET NEURON will not fund the establishment of large cohorts, but the use of existing cohorts, biobanks/brain banks and exploitation of existing datasets is encouraged. Appropriate access to relevant, well-characterized patient populations or suitable biomaterial collections must be demonstrated. The proposal should describe plans to make data available for the research and clinical communities. It is recommended that the appropriate European infrastructures are contacted early in the planning of the projects; the following are potentially of interest for the applicants of this call: EBRAINS (focused on data and tools for brain-related research), INFRAFRONTIER (focused on modelling of human diseases) with the European Mouse Mutant Archive (EMMA), ECRIN (focused on clinical research), EATRIS-ERIC (focused on translational medicine), BBMRI-ERIC (focused on biobanking), and ELIXIR (focused on data sharing).

The ERA-NET NEURON seeks to strengthen patient engagement in research. All applications should include a description of expected outcomes with potential relevance for patients. Applicants are expected to engage patients, their care givers or patient organisations as appropriate in the research. Meaningful patient engagement can occur at the level of research planning, conducting research or disseminating research results. Patient representatives will assess patient engagement aspects, the feasibility, and the relevance of the full proposals from a patient perspective.

### **3. Application**

#### **3.1 Eligibility**

Joint transnational research proposals may be submitted by research teams working in universities (or other higher education institutions), non-university public or private research organisations, hospitals or foundations, and commercial companies, particularly small and medium-sized enterprises. The eligibility of the afore-mentioned institutions, together with details of eligible costs (e.g. personnel, material, consumables, travel money, investments), are subject to the administrative requirements of individual funding organisations and will therefore differ. Please note that, for some funding organisations,

---

<sup>3</sup> In order to improve the quality of the proposals in terms of sex and gender considerations, applicants are encouraged to visit the following link and complete the modules: <https://www.cihr-irsc.gc.ca/e/49347.html>

<sup>4</sup> Eligibility and funding requirements for clinical trials vary between the partner countries. Clarification may be obtained from the individual funding organisations.

commercial companies are not eligible or are only eligible under certain conditions (e.g. only in partnership with academic institutions in the consortium). Clarification should be obtained from the individual funding organisations (see contact details below). It is strongly recommended to carefully read the [funder-specific regulations](#) regarding eligibility and funding and to contact the respective funding organisations, since additional national/regional procedures might be mandatory.

Only transnational projects will be funded. Each consortium submitting a proposal must comprise a minimum of three research partners eligible for funding by organisations listed in this call text (see above). Involvement of promising early career researchers (ECRs)<sup>5</sup> as consortium partners is highly encouraged and will be part of the evaluation criteria (see section 4). The eligible research partners must be from at least three different participating countries. The total number of research partners in a consortium is limited to five, including partners participating with their own expenses. No more than two consortium partners can be from the same country. Attention should be paid to respect gender balance among the partners of a consortium.

The ERA-NET NEURON strives to strengthen a global Brain Research Area by including as many partner countries as possible in its funding scheme. Therefore, consortia including at least one partner from countries that are to date underrepresented in this funding scheme (Croatia, Hungary, Latvia, Lithuania, Romania, Slovakia, Taiwan and Türkiye) may increase the total number of partners to six.

Applicant partners who are not eligible for funding from their national/regional funding organisations or from countries/regions that are not involved in this call, may participate in consortia only if a) their participation clearly provides an added value to the consortium, and b) they have secured a budget for their part in the project. Such potential partners are not considered in the minimum number of three research partners mentioned above. In any case, the total number of research partners in one consortium must not exceed five, or six, if partners from the underrepresented countries (listed above) are included.

Each consortium should have the critical mass to achieve ambitious scientific goals and **should clearly demonstrate added value** from working together. Each consortium must nominate a coordinator who represents the consortium externally and is responsible for its internal management (e.g. the application procedure, coordination of consortium agreement drafting, Data Management Plan, reporting). The consortium coordinator must be eligible for funding from one of the organisations listed in this call text.

A single proposal must be submitted by the consortium coordinator to the NEURON Joint Call Secretariat. The individual research partners in a consortium will be funded by the respective national/regional NEURON funding organisation(s). Eligibility criteria are the matter of individual partner funding organisations and additional national/regional regulations and requirements may apply.

### **The inclusion of a research partner that is not eligible for funding according to the specific**

---

<sup>5</sup> up to 7 years of experience since completion of PhD or medical specialization diploma at the date of the launch of this call and a scientific track record showing great promise. Allowed extensions 18 months maternity leave for each child born, documented time of paternity leave for each child born (an official document must be submitted only upon explicit request), duration of long-term illness or national service, duration of clinical training with a maximum of 4 years). **Please check the funder specific regulations for the national/regional eligibility criteria that apply.**

**regulations of its respective funding organisation may result in the rejection of the entire proposal without further review.** Therefore, applicants are strongly advised to follow the instructions in the [funder-specific regulations](#) section, published on the NEURON website and to contact their national/regional funding organisation to confirm eligibility rules before submitting a proposal.

Only projects that fulfil the legal and ethical international/EU regulations (including ethical standards and guidelines in Horizon EUROPE) as well as national and institutional regulations and standards will be funded. All proposed activities including those undertaken in countries outside the EU must comply with EU regulations (see Annex I of the full proposal template). Ethical approval(s) and/or a positive vote(s) must be obtained from the relevant national or local ethics committee(s) prior to the start of respective studies.<sup>6</sup> The obtainment of ethical clearance will be queried by ERA-NET NEURON. All procedures involving human beings must conform to the Helsinki Declaration.

### 3.2 Submission of joint transnational proposals

There will be a **two-stage procedure** for joint applications: **pre-proposals** and **full proposals**. In both cases, one joint **proposal document** (in English) shall be prepared by the partners of a joint transnational proposal, and must be submitted to the Joint Call Secretariat by the coordinator.

Pre-proposals must be submitted in electronic format no later than **6<sup>th</sup> March, 2025** (14:00 CET) via the [electronic submission system](#). All fields must be completed using **DIN-A4; font: Arial, 10pt; single-spaced, page limits. Pre-proposals that do not meet the formal criteria will be rejected from the call process without further review.**

**NOTE:** Full proposal submissions will be accepted only from those applicants **explicitly invited** by the Joint Call Secretariat.

The information given in the pre-proposal is binding. Thus, any fundamental changes between the pre- and full proposals stages concerning the composition of the consortia, objectives of the project or requested budget must be communicated to the Joint Call Secretariat and approved by the respective funding organisations **with detailed justifications** and will only be allowed **in exceptional cases** before passing to the evaluation stage.

### 3.3 Further information

For further details, please refer to the respective submission forms available through the NEURON [website](#). If you need additional information, please contact the Joint Call Secretariat. Finally, national/regional organisations may set special requirements for their applicants. Applicants are therefore strongly advised to review the instructions contained in the [funder-specific information](#) published on the NEURON [website](#) and to contact their national/regional funding organisation for further

---

<sup>6</sup> Requirements for ethical approvals may vary between the partner countries. Please refer to the funder-specific information or contact the individual funding organisations.

information (see Annex I for contact details).

## 4. Evaluation and decision

The review process will be in two stages.

### 4.1 Formal check of pre- and full proposals

The Joint Call Secretariat will check the proposals to ensure that they meet the call's formal criteria (e.g. date of submission; the number of participating partners and countries/regions; inclusion of all necessary information according to the respective templates in English). The Joint Call Secretariat will provide online access to the proposals to the national/regional funding organisations, which will perform a formal eligibility check for compliance with their respective regulations.

The Joint Call Secretariat and national/regional funding organisations will perform cross-checks in parallel submissions to other joint transnational calls (e.g. ERDERA, JPND, EP PerMed and others) and national calls. Applicants shall avoid applying for the same research activities to different calls. Double funding is not allowed.

Proposals not meeting the formal criteria described above will be rejected at this stage. Proposals passing this step will be forwarded to the peer review for evaluation.

### 4.2 Peer review of pre- and full proposals

The reviewers will assess if the projects are within the scope of the call and evaluate them using the following criteria:

#### 1. Excellence

- Scientific quality of the approach and methodology
- Quality of the experimental design and data analysis
- Novelty of the scientific concept/hypotheses
- Competence and experience of participating research partners in the field(s) of the proposal (previous work in the field, specific technical expertise)

#### 2. Impact

- Potential impact of the expected results on clinical and other health-related applications
- Added value of transnational collaboration
- Inclusion of early career researchers (ECRs)
- Potential impact for patients; patient involvement, diversity and ethical aspects

#### 3. Quality and efficiency of the implementation

- Feasibility of the project



- Coherence and effectiveness of the work plan, including appropriateness of the allocation of tasks, resources, time frame and related risk analysis
- Quality and added value of collaborative and multi-disciplinary interactions within the consortium
- Appropriateness of the management structures and procedures

ERA-NET NEURON strives to fund reproducible and solid scientific outputs, and our evaluation criteria value the methodological rigour of the experimental approaches proposed.

## 4.3 Decision

### 4.3.1 Pre-proposals

Eligible pre-proposals will be reviewed using the above-mentioned evaluation criteria via a written (remote) peer review process. Preferably, each pre-proposal will be reviewed by at least three reviewers. Based on the scores in the written reviews, a ranking list will be established. By mid-May 2025, the coordinators of the selected proposals will be invited by the Joint Call Secretariat to submit a full proposal before **26<sup>th</sup> June 2025** (14:00 CEST).

### 4.3.2 Full proposals

The international Peer Review Panel will evaluate the full proposals based on the above-mentioned evaluation criteria and establish a ranking list based on scientific assessment at the panel meeting. Additionally, expert patient reviewers will assess the patient-relevant aspects of the full proposals and an Ethics board will give recommendations on the ethical aspects of the full proposals. A short list of proposals will be identified as recommended for funding based on the ranking list. The Call Steering Committee will determine the projects to be funded, considering the national budgets' availability.

## 5. Funding procedure / Responsibilities / Reporting requirements

### 5.1 Funding procedure

Successful research groups will be funded directly by the respective funding organisations.

Funding is expected to start by early to mid-2026. Projects should be designed to be achievable during a maximum funding period of **three years**.

Funding will be administered according to the terms and conditions of the responsible funding organisations, considering all other applicable regulations and legal requirements.

## 5.2 Responsibilities

Within a joint proposal, each research partner will be the contact person for the respective national/regional funding organisation. The coordinators of funded projects together with the relevant funding organisations shall make every effort to seek a common start date for all research groups in a consortium.

After the evaluation and selection procedures are completed, each funded consortium is required to draft a Consortium Agreement (CA) and a Data Management Plan (DMP). The CA will determine a common project start date, manage the delivery of project activities, finances and intellectual property rights (IPR), and avoid disputes that might be detrimental to the completion of the project. **With the first annual report, the coordinator must provide the DMP and the CA signed by all parties to the Joint Call Secretariat.** Please note that some funding organisations may require the submission of a DMP, CA, and/or ethical approval at an earlier time point. Please read carefully the [funder-specific information](#) section.

## 5.3 Reporting Requirements

On behalf of the research consortium, the consortium coordinator will be required to submit to the Joint Call Secretariat annual scientific progress reports, as well as a final report at the end of the project. Additionally, the individual partners may be required to submit reports separately to their national/regional funding organisation. In the latter case, reporting guidance will be forwarded by the relevant funding organisation, as applicable.

**Annual reports** must be submitted by 30<sup>th</sup> April, starting in 2027. **Final reports** must be submitted at the latest six months after the end of the project. Annual reports do not need to be submitted if the project ends between January and March of the last year. In the latter case, the submission of a final report three months after the end of the project will suffice.

In exceptional cases, partners may be granted runtimes of different start and/or duration according to the national funders' decision. It is the task of the coordinators to determine, in agreement with the consortia, a formal end date for project completion; usually the latest end date of individual national contracts. Coordinators will be informed about this procedure by the Joint Call Secretariat and will receive the report templates in due course.

The coordinators will be asked to present a progress report during a **midterm symposium**. Attendance is **mandatory for all coordinators and project partners (represented by principal investigators or other team members)**. Failure to comply with this requirement may result in administrative and/or financial sanctions according to the rules of each funding organisation. Students and postdoctoral researchers working on the projects are welcome to join the midterm symposium. Accordingly, travel expenses to attend the symposium should be included in the proposal budget plans.

Funding recipients must ensure that all outcomes (publications, etc.) of transnational NEURON projects include a proper acknowledgement of ERA-NET NEURON and the respective funding partner

organisations. All the publications resulting from funded projects must be published in adherence to the [EC Open Science Policy](#) and [specific rules of the funding agencies](#).

#### 5.4 General data protection regulation

Applicants are informed that their personal data submitted in their application to the call are processed in accordance with article 6.1 (e) and (c) of the General Data Protection Regulation (GDPR) (2016/679)<sup>7</sup>, and for the purposes of:

- processing and evaluating the application where processing shall be lawful only if and to the extent that processing is necessary for the performance of a task carried out in the public interest or in the exercise of official authority vested in the controller;
- administering any subsequent funding award;
- managing the funding organisation's relationship with them;
- analysing and evaluating the call;
- providing aggregate data to national and European surveys and analyses on the funded projects.

The Call Steering Committee will not share personal data with third parties other than parties necessary for the execution of the joint transnational call and parties required by national laws. The funding organisations outside of the European Union who are not subject to GDPR will comply with GDPR on the basis of an adequacy decision or on the basis of standard data protection clauses adopted by the commission in accordance with the examination procedure or pursuant to Article 49 of the GDPR in relation to the above activities including evaluators, auditors and the European Commission (or its agencies).

---

<sup>7</sup> Last name, first name of the researchers, date of birth, professional contact information, degree(s), position (current and previous), fields of activity, place of work, organisation, address(es), curriculum vitae, ORCID number, name and reference of projects, pre-proposals, project proposals (scientific document, administrative and financial appendix).

## Annex I. Contact details

Please note that [funder-specific requirements](#) might apply to this call. **Compliance with the national/regional regulations specified in the funder-specific information is mandatory.** A parallel national/regional application or additional requirements may be requested by certain funding organisations (see table page 3). **We strongly advise you to contact your national/regional representative prior to submitting a pre-proposal:**

Country /region	Contact person(s)	Funding organisations contact Details
Australia	Dr. Patricia Ridgway	National Health and Medical Research Council (NHMRC) <a href="mailto:international@nhmrc.gov.au">international@nhmrc.gov.au</a>
Belgium (French-Speaking Community)	Dr Florence Quist Dr Joël Groeneveld	Fonds de la Recherche Scientifique – FNRS (F.R.S.-FNRS) <a href="mailto:International@frs-fnrs.be">International@frs-fnrs.be</a> +32(0)2 504 93 51 +32(0)2 504 92 70
Croatia	Mateo A. Bosnić	Ministry of Science, Education and Youth (MSEY) <a href="mailto:mateoante.bosnic@mzom.hr">mateoante.bosnic@mzom.hr</a> +38514594166
France	Dr. Catherine Marquer Dr. Gaëlle Provenzano	French National Research Agency (ANR) Health & Biology Department <a href="mailto:neuroncalls@agencerecherche.fr">neuroncalls@agencerecherche.fr</a> +33 1 75 77 49 41
Germany	Dr. Sophia Schach Dr. Vera Mönter-Telgen	Federal Ministry of Education and Research (BMBF) <a href="mailto:neuron-eranet@dlr.de">neuron-eranet@dlr.de</a> +49 228 3821 2184
Germany	Dr. Anke Ley	German Research Foundation (DFG) <a href="mailto:anke.ley@dfg.de">anke.ley@dfg.de</a> Tel. +49 (228) 885-3197 <a href="http://www.dfg.de">www.dfg.de</a>
Hungary	Zsuzsanna Kürti	National Research, Development and Innovation Office (NKFIH)  E-Mail: <a href="mailto:nemzetkozi@nkfi.gov.hu">nemzetkozi@nkfi.gov.hu</a>
Ireland	Dr. Siobhán Hackett Dr. Amanda Daly	Health Research Board (HRB) <a href="mailto:eujointprogrammes@hrb.ie">eujointprogrammes@hrb.ie</a>
Israel	Dr. Liron Even-Faitelson	Chief Scientist Office - Ministry of Health (CSO-MOH) <a href="https://www.gov.il/he/departments/general/international_cooperations">https://www.gov.il/he/departments/general/international_cooperations</a> <a href="mailto:liron.ef@moh.gov.il">liron.ef@moh.gov.il</a> 972-2-508-2168
Italy	Chiara Ciccarelli Simona Bifulchi	Italian Ministry of Health (IT-MoH) <a href="mailto:c.ciccarelli@sanita.it">c.ciccarelli@sanita.it</a> <a href="mailto:s.bifulchi@sanita.it">s.bifulchi@sanita.it</a>
Latvia	Dr. Uldis Berkis Dr. Maija Bundule	Latvian Council of Science (LZP) <a href="mailto:Uldis.Berkis@lzp.gov.lv">Uldis.Berkis@lzp.gov.lv</a> +371- 29472349 <a href="mailto:Maija.Bundule@lzp.gov.lv">Maija.Bundule@lzp.gov.lv</a> +371- 26514481
Lithuania	Živilė Ruželė	Research Council of Lithuania (LMT) Phone: +370 676 14383 ; e-mail: <a href="mailto:zivile.ruzele@lmt.lt">zivile.ruzele@lmt.lt</a>

		<a href="https://lmt.lrv.lt/en">https://lmt.lrv.lt/en</a>
Norway	Dr. Alexandra Bjørk-Skaflestad	The Research Council of Norway (RCN) <a href="mailto:alb@rcn.no">alb@rcn.no</a> +47 48 144 767
Poland	Dr Marcin Chmielewski	National Centre for Research and Development (NCBR) +48 571 226 666, +48 22 39 07 109, e-mail: <a href="mailto:marcin.chmielewski@ncbr.gov.pl">marcin.chmielewski@ncbr.gov.pl</a>
Romania	Mihaela Manole	Executive Agency for Higher Education, Research, Development and Innovation Funding (UEFISCDI) <a href="mailto:Mihaela.manole@uefiscdi.ro">Mihaela.manole@uefiscdi.ro</a> +40 213 238 63
	Nicoleta Dumitrache	<a href="mailto:Nicoleta.dumitrache@uefiscdi.ro">Nicoleta.dumitrache@uefiscdi.ro</a> +40 213 238 86
Slovakia	Katarina Bibova	Slovak Academy of Sciences (SAS) <a href="mailto:bibova@up.upsav.sk">bibova@up.upsav.sk</a> +421 2 5751 0136
	Silvia Kecerova	<a href="mailto:kecerova@up.upsav.sk">kecerova@up.upsav.sk</a> <a href="http://www.sav.sk">www.sav.sk</a>
Switzerland	Dr. Francis Parlange	Swiss National Science Foundation (SNSF) Unit Projects Life Sciences <a href="mailto:francis.parlange@snf.ch">francis.parlange@snf.ch</a> +41 31 308 23 85
	Dr. Carolin von Schoultz	<a href="mailto:carolin.vonschoultz@snf.ch">carolin.vonschoultz@snf.ch</a> +41 31 308 23 25
Taiwan	Dr. Ching-Mei TANG	National Science and Technology Council (NSTC) <a href="https://www.nstc.gov.tw/?l=en">https://www.nstc.gov.tw/?l=en</a> <a href="mailto:cmtom@nstc.gov.tw">cmtom@nstc.gov.tw</a>
Türkiye	Dr. Recep Emrah Çevik	The Scientific and Technological Research Council of Türkiye (TÜBİTAK) <a href="http://www.tubitak.gov.tr">www.tubitak.gov.tr</a> <a href="mailto:emrah.cevik@tubitak.gov.tr">emrah.cevik@tubitak.gov.tr</a>
UK	Dr. Karen Brakspear	Medical Research Council (MRC), as part of United Kingdom Research and Innovation Email: <a href="mailto:Karen.brakspear@mrc.ukri.org">Karen.brakspear@mrc.ukri.org</a>
	Dr. Bethan Davies	Email: <a href="mailto:Bethan.davies@mrc.ukri.org">Bethan.davies@mrc.ukri.org</a>

## Annex II. Anticipated amount of funding provided by each funding organisation

The intended contribution by each participating funding organisation to be used for the joint transnational call for research projects is listed below.

Partner Country / Region	Funding organisation	Anticipated amount of funding (for 3 years)	Anticipated number of fundable research groups
Australia	National Health and Medical Research Council (NHMRC)	~ 1.800.000 € (\$ AUD 3.000.000)	1 or more
Belgium	Fonds de la Recherche Scientifique-FNRS (F.R.S.-FNRS)	200.000€	1
Croatia	Ministry of Science, Education and Youth (MSEY)	200.000€	1
France	French National Research Agency (ANR)	1.800.000€	6-7
Germany	Federal Ministry of Education and Research (BMBF)	3.000.000€	8-9
Germany	German Research Foundation (DFG)	1.220.000€	3
Hungary	National Research, Development, and Innovation Office (NKFIH)	300.000€	1-2
Ireland	Health Research Board (HRB)	530.000€	1-2
Israel	Ministry of Health (CSO-MOH)	300.000€	2
Italy	Italian Ministry of Health (IT-MoH)	1.600.000€	4
Latvia	Latvian Council of Science (LZP)	600.000€	2
Lithuania	Research Council of Lithuania (LMT)	300.000€	2
Norway	The Research Council of Norway (RCN)	500.000€	1-2
Poland	National Centre for Research and Development (NCBR)	1.500.000€	1-5
Romania	Executive Agency for Higher Education, Research, Development & Innovation Funding (UEFISCDI)	500.000€	1-2
Slovakia	Slovak Academy of Sciences (SAS)	120.000€	1
Switzerland	Swiss National Science Foundation (SNSF)	~1.000.000€ (CHF 1.000.000)	3-4
Taiwan	National Science and Technology Council (NSTC)	810.000€	2-3
Türkiye	The Scientific and Technological Research Council of Türkiye (TUBITAK)	300.000€	2-3
UK	Medical Research Council (MRC)	~2.300.000€ (£ 2.000.000)	8-9

### Annex III. Call Timetable

#### Pre-proposal stage (I)

<b>December 05, 2024</b>	Preliminary Announcement of the Joint Transnational Call
<b>January 07, 2025</b>	Launch of the Joint Transnational Call
<b>March 06, 2025</b>	Deadline (submission of pre-proposals) 14:00 CET
<b>Mid-May, 2025</b>	Formal invitation to submit a full proposal

#### Full proposal stage (II)

<b>June 26, 2025</b>	Submission deadline of full proposals 14:00 CEST
<b>September, 2025</b>	Peer Review Panel meeting to assess the full proposals
<b>October/November 2025</b>	Final funding decision by the CSC and start of national administrative procedures
<b>Early - Mid 2026</b>	Start of funding